September 21, 2026

IDEXX Laboratories, Inc. (IDXX)

⚠️ No article content returned.

..

Pfizer, Inc. (PFE) Stock Analysis: Exploring a 6.22% Dividend Yield Amidst Healthcare Sector Shifts

Pfizer, Inc. (NYSE: PFE), a stalwart in the healthcare sector, continues to capture investor interest with its robust 6.22% dividend yield, positioning itself as a potentially rewarding option for income-focused..

Thermo Fisher Scientific Inc (TMO) Stock Analysis: Navigating the Market with Strong Buy Ratings and Robust Revenue Growth

As a leading player in the healthcare sector, Thermo Fisher Scientific Inc. (NYSE: TMO) stands at the forefront of the diagnostics and research industry. With a formidable market capitalization of..

Takeda Pharmaceutical Company L (TAK) Stock Analysis: Exploring a 17.6% Potential Upside and Strong Revenue Growth

With a rich history dating back to its founding in 1781, Takeda Pharmaceutical Company Limited (NYSE: TAK) stands as a global powerhouse in the healthcare sector, specifically within the specialty..

Sanofi (SNY) Stock Analysis: Exploring a 26.46% Upside Potential in the Healthcare Sector

Sanofi (NASDAQ: SNY), a titan in the healthcare sector, has caught the attention of investors with its substantial market cap of $101.79 billion and a compelling potential upside of 26.46%,..

Investor Outlook: Edwards Lifesciences (EW) Sees 14.39% Upside with Strong Buy Ratings

Edwards Lifesciences Corporation (NYSE: EW), a leader in the medical devices sector with a market capitalization of $50.82 billion, is making waves in the healthcare industry. Known for its innovative..

argenx SE (ARGX) Stock Analysis: Exploring a Promising 19.21% Potential Upside

Investors seeking exposure to the biotech sector might find argenx SE (ARGX) an intriguing opportunity. Based in the Netherlands, this commercial-stage biopharma company is making significant strides in the treatment..

Elevance Health, Inc. (ELV) Stock Analysis: Insights into a Healthcare Giant with Nearly 10% Upside Potential

Elevance Health, Inc. (NYSE: ELV) stands as a formidable player in the healthcare plans industry, boasting a market capitalization of $89.12 billion. As a health benefits company operating in the..

Danaher Corporation (DHR) Stock Analysis: A Healthcare Giant with an 8% Upside Potential

Danaher Corporation (NYSE: DHR), a formidable player in the healthcare sector specializing in diagnostics and research, stands out with its robust market capitalization of $148.9 billion. With its current stock..

Gilead Sciences, Inc. (GILD) Stock Analysis: Exploring Revenue Growth and Strategic Collaborations

Gilead Sciences, Inc. (NASDAQ: GILD) has long been a titan in the healthcare sector, specifically within the drug manufacturing industry. Headquartered in Foster City, California, Gilead has carved out a..

Zoetis Inc. (ZTS) Stock Analysis: Exploring a 34% Potential Upside for Investors

Zoetis Inc. (NYSE: ZTS), a leading player in the healthcare sector, specifically within the drug manufacturers – specialty & generic industry, stands as a compelling consideration for investors seeking growth..

CVS Health Corporation (CVS) Stock Analysis: Unlocking a 30.89% Upside Potential in Healthcare

As CVS Health Corporation (NYSE: CVS) continues to solidify its presence in the healthcare sector, individual investors are presented with an interesting opportunity to explore a potential upside of 30.89%...

Amgen Inc. (AMGN) Stock Analysis: Navigating Growth with a Robust Pipeline and a 2.61% Dividend Yield

Amgen Inc. (NASDAQ: AMGN), a titan in the healthcare sector, continues to capture the attention of investors with its robust portfolio of therapeutics and promising financial metrics. Headquartered in Thousand..

Abbott Laboratories (ABT) Stock Analysis: Robust Growth and a 17% Upside Potential Beckon Investors

Abbott Laboratories (NYSE: ABT), a stalwart in the healthcare sector, continues to capture investor interest with its impressive market cap of $178.73 billion and a robust array of healthcare products..

Novartis AG (NVS) Investor Outlook: Evaluating the 11.53% Potential Upside and Robust Dividend Yield

Novartis AG (NYSE: NVS), a powerhouse in the healthcare sector, operates within the global pharmaceutical landscape. With its market capitalization standing at an impressive $266.8 billion, Novartis continues to be..

Boston Scientific Corporation (BSX) Stock Analysis: Unveiling a 42.5% Upside Potential for Investors

Boston Scientific Corporation (NYSE: BSX), a prominent player in the healthcare sector specializing in medical devices, offers a compelling investment case with a significant upside potential of 42.5%. As the..

Johnson & Johnson (JNJ) Stock Analysis: Navigating through Healthcare with a Robust Growth and Dividend Outlook

Johnson & Johnson (NYSE: JNJ), a stalwart in the healthcare sector, continues to capture investor attention with its expansive market cap of $650.65 billion. As a major player in the..

Global property capital shifts towards quality as European retail regains attention

Global real estate activity is recovering, with capital increasingly targeting high-quality assets and European retail properties supported by strong locations, limited supply and changing consumer demand...

AstraZeneca’s Klygefa recommended for EU approval in generalised myasthenia gravis

The EMA’s CHMP has recommended Klygefa (gefurulimab) for approval as an add-on treatment for adults with AChR antibody-positive generalised myasthenia gravis, based on Phase III PREVAIL trial results...

Verici Dx expands diagnostics portfolio with Q4 launch of TranscripTx

Verici Dx plans to launch TranscripTx in Q4 2026, adding a transplant-focused multi-gene test to its commercial portfolio. The product leverages the company’s RNA diagnostics expertise, clinical data repository and..
Search

Funds

September 21, 2026

Global property capital shifts towards quality as European retail regains attention

Global real estate activity is recovering, with capital increasingly targeting high-quality assets and European retail properties supported by strong locations, limited supply and changing consumer demand...

AstraZeneca’s Klygefa recommended for EU approval in generalised myasthenia gravis

The EMA’s CHMP has recommended Klygefa (gefurulimab) for approval as an add-on treatment for adults with AChR antibody-positive generalised myasthenia gravis, based on Phase III PREVAIL trial results...

Verici Dx expands diagnostics portfolio with Q4 launch of TranscripTx

Verici Dx plans to launch TranscripTx in Q4 2026, adding a transplant-focused multi-gene test to its commercial portfolio. The product leverages the company’s RNA diagnostics expertise, clinical data repository and biological samples, supporting both patient management and therapeutic development...
Search

Funds

September 21, 2026

FTSE 100

Funds